US Patent Issued to Icahn School of Medicine at Mount Sinai, The United States Government as Represented by the Department of Veterans Affairs on July 7 for "Oxadiazolyl dihydropyrano[2,3-bpyridine inhibitors of HIPK2 for treating kidney fibrosis" (New York, California Inventors)

ALEXANDRIA, Va., July 7 -- United States Patent no. 12,673,956, issued on July 7, was assigned to Icahn School of Medicine at Mount Sinai (New York) and The United States Government as Represented by the Department of Veterans Affairs (Washington).

"Oxadiazolyl dihydropyrano[2,3-bpyridine inhibitors of HIPK2 for treating kidney fibrosis" was invented by Richard T. Beresis (San Francisco), John Cijiang He (Forest Hills, N.Y.) and Kyung Lee (Bronx, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds are (3-aryl-1,2,4-oxadiazol-5-yl)-3,4-dihydro-2H-pyrano[2,3-b]pyridines of the following structure:in which Ar is aryl or het...